BACKGROUND/AIM Hypercholesterolemia is characterized by changes in lipid profile, nitric oxide pathway, and oxidative stress markers, but functions of high-density lipoprotein (HDL) were not well established in hypercholesterolemic subjects treated with atorvastatin. In this study, we aimed to evaluate effects of atorvastatin treatment on functionality of HDL, oxidative stress, and endothelial ...

Atherosclerotic heart disease includes acute coronary syndromes and hyperlipidmia. The prescription of patients with atherosclerotic heart disease mostly contains atorvastatin and clopidogrel. Aim of this study is to estimate clinical pharmacokinetic interaction between atorvastatin and clopidogrel in atherosclerotic heart disease patients. This study was conducted by estimating the carboxylic ...

Clinical trials with statins have demonstrated significant reductions in cardiovascular events. Remnant lipoproteins are independent predictors of cardiovascular events. Because of the paucity of data on the effect of statins on remnant lipoproteins, we tested the effect of pravastatin, simvastatin, and atorvastatin on remnant lipoprotein cholesterol (RLP-C) levels in a randomized crossover stu...

Guinea pigs were fed 15% (w/W) fat, high in lauric and myristic acids, a diet known to produce hypercholesterolemia in these animals. The diet was given alone or in combination with four doses of atorvastatin equivalent to 1, 3, 10, and 20 mg/kg per day. Atorvastatin reduced plasma LDL cholesterol concentrations by 46, 50, 53, and 70%, respectively (P < 0.001). Plasma apoB concentrations were r...

Abstract The aim of this study was to evaluate the effects increasing concentrations three pure statins on in vitro methane production and rumen fermentation. atorvastatin, rosuvastatin simvastatin at (1, 10, 100 mg/L culture fluid) were evaluated using 24 h batch incubation buffered fluid with a 70:30 forage:concentrate substrate. All tested demonstrated ability reduce methanogenesis. Methane ...

The underlying mechanisms behind the effect of atorvastatin on patients with coronary slow flow (CSF) remain largely unknown. To investigate the possible underlying molecular mechanisms 108 patients were divided into atorvastatin group and control group. Coronary flow was quantified according to corrected TIMI frame count (CTFC). Serum high sensitivity C-reactive protein (hs-CRP), lipids, ET-1,...

BACKGROUND In 2011, Manitoba implemented a province-wide program of physician detailing and free sampling for generic atorvastatin to increase use of this generic statin. We examined the impact of this unique combined program of detailing and sampling for generic atorvastatin on the use and cost of statin medicines, market share of generic atorvastatin, the choice of starting statin for new use...

BACKGROUND Statins (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors) have been used for a decade to lower low-density lipoprotein (LDL) cholesterol levels and to improve cardiovascular disease and clinical outcomes. OBJECTIVE To evaluate the safety profile of atorvastatin (Lipitor). METHODS Data were pooled for 21 completed (2502 patients) and 23 ongoing (1769 patients)...

3-hydroxy-3-methylglutaryl-coa reductase inhibitors (statins), are effective serum cholesterol-lowering agents which also have anti-inflammatory properties. the objective of this study was to evaluate the effect of atorvastatin on bronchial hyperresponsiveness. adult patients (age 14 to 65 years) with bronchial hyperresponsiveness (bhr) diagnosis based on the spirometry with methacholine challe...

The concept that hepatic cholesterol synthesis regulates hepatocyte assembly and secretion of apoB-containing lipoproteins remains controversial. The present study was carried out in HepG2 cells to examine the regulation of apoB secretion by the HMG-CoA reductase inhibitor atorvastatin. ApoB accumulation in the media was decreased by 24% and 36% at 10 microm (P < 0.02) and 20 microm (P < 0.01) ...